RU2018112993A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018112993A3 RU2018112993A3 RU2018112993A RU2018112993A RU2018112993A3 RU 2018112993 A3 RU2018112993 A3 RU 2018112993A3 RU 2018112993 A RU2018112993 A RU 2018112993A RU 2018112993 A RU2018112993 A RU 2018112993A RU 2018112993 A3 RU2018112993 A3 RU 2018112993A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232629P | 2015-09-25 | 2015-09-25 | |
| US62/232,629 | 2015-09-25 | ||
| PCT/EP2016/072616 WO2017050938A1 (en) | 2015-09-25 | 2016-09-22 | Compounds and methods for inhibiting jak |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018112993A RU2018112993A (ru) | 2019-10-28 |
| RU2018112993A3 true RU2018112993A3 (enExample) | 2020-01-30 |
| RU2760359C2 RU2760359C2 (ru) | 2021-11-24 |
Family
ID=56979589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018112993A RU2760359C2 (ru) | 2015-09-25 | 2016-09-22 | Соединения и способы для ингибирования JAK |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US9714236B2 (enExample) |
| EP (2) | EP4219482A1 (enExample) |
| JP (1) | JP6767491B2 (enExample) |
| KR (2) | KR20250035597A (enExample) |
| CN (4) | CN111606893B (enExample) |
| AR (1) | AR106138A1 (enExample) |
| AU (1) | AU2016328764B2 (enExample) |
| BR (1) | BR112018005833B1 (enExample) |
| CA (1) | CA2995430C (enExample) |
| DK (1) | DK3353168T3 (enExample) |
| ES (1) | ES2956642T3 (enExample) |
| MX (1) | MX375724B (enExample) |
| PT (1) | PT3353168T (enExample) |
| RU (1) | RU2760359C2 (enExample) |
| TW (1) | TWI740843B (enExample) |
| WO (1) | WO2017050938A1 (enExample) |
| ZA (1) | ZA201800782B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250035597A (ko) * | 2015-09-25 | 2025-03-12 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak를 억제하기 위한 화합물 및 방법 |
| US10513509B2 (en) | 2016-05-26 | 2019-12-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| MX390625B (es) * | 2017-01-17 | 2025-03-19 | Astrazeneca Ab | Inhibidores selectivos de jak1. |
| JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
| CN118580223A (zh) * | 2018-07-18 | 2024-09-03 | 阿斯利康(瑞典)有限公司 | 抑制jak的化合物的昔萘酸盐 |
| CN112823159B (zh) * | 2018-09-21 | 2024-03-01 | 上海轶诺药业有限公司 | 一类具有激酶抑制活性的芳香杂环类化合物 |
| KR102195348B1 (ko) * | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| MX2021012749A (es) * | 2019-04-19 | 2021-11-18 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidor selectivo de la jak1 cinasa. |
| CN110627775A (zh) * | 2019-10-24 | 2019-12-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN111961037B (zh) * | 2020-09-17 | 2021-09-21 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的药物化合物 |
| CN114269736B (zh) * | 2020-11-26 | 2024-02-02 | 科辉智药(深圳)新药研究中心有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| MX2023010642A (es) | 2021-03-11 | 2023-11-28 | Janssen Pharmaceutica Nv | Lorpucitinib para uso en el tratamiento de trastornos mediados por jak. |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| WO2025230951A1 (en) * | 2024-04-29 | 2025-11-06 | Icahn School Of Medicine At Mount Sinai | Method of treating adenoid cystic carcinoma |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2560454C (en) * | 2004-03-30 | 2013-05-21 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| EP2388259A1 (en) | 2005-10-28 | 2011-11-23 | AstraZeneca AB | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
| WO2007089768A2 (en) * | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
| ME00811B (me) * | 2006-12-08 | 2012-03-20 | Novartis Ag | JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE |
| US9908884B2 (en) * | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| US20130225615A1 (en) * | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| JP2014500254A (ja) * | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体 |
| SG190839A1 (en) * | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012116247A1 (en) * | 2011-02-25 | 2012-08-30 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
| WO2012177606A1 (en) * | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| CN104334191A (zh) | 2012-03-29 | 2015-02-04 | 纽约市哥伦比亚大学托管会 | 治疗毛发脱落疾病的方法 |
| KR20250035597A (ko) * | 2015-09-25 | 2025-03-12 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak를 억제하기 위한 화합물 및 방법 |
-
2016
- 2016-09-22 KR KR1020257006096A patent/KR20250035597A/ko active Pending
- 2016-09-22 ES ES16770031T patent/ES2956642T3/es active Active
- 2016-09-22 KR KR1020187008186A patent/KR102774784B1/ko active Active
- 2016-09-22 CN CN202010629290.1A patent/CN111606893B/zh active Active
- 2016-09-22 CN CN202010626114.2A patent/CN111848586B/zh active Active
- 2016-09-22 MX MX2018003590A patent/MX375724B/es active IP Right Grant
- 2016-09-22 AU AU2016328764A patent/AU2016328764B2/en active Active
- 2016-09-22 EP EP23150992.8A patent/EP4219482A1/en active Pending
- 2016-09-22 DK DK16770031.9T patent/DK3353168T3/da active
- 2016-09-22 US US15/272,554 patent/US9714236B2/en active Active
- 2016-09-22 PT PT167700319T patent/PT3353168T/pt unknown
- 2016-09-22 CA CA2995430A patent/CA2995430C/en active Active
- 2016-09-22 RU RU2018112993A patent/RU2760359C2/ru active
- 2016-09-22 EP EP16770031.9A patent/EP3353168B1/en active Active
- 2016-09-22 JP JP2018535238A patent/JP6767491B2/ja active Active
- 2016-09-22 CN CN202010629286.5A patent/CN111646980B/zh active Active
- 2016-09-22 CN CN201680055491.7A patent/CN108368091B/zh active Active
- 2016-09-22 WO PCT/EP2016/072616 patent/WO2017050938A1/en not_active Ceased
- 2016-09-22 BR BR112018005833-5A patent/BR112018005833B1/pt active IP Right Grant
- 2016-09-23 TW TW105130891A patent/TWI740843B/zh active
- 2016-09-23 AR ARP160102919A patent/AR106138A1/es active IP Right Grant
-
2017
- 2017-05-22 US US15/601,324 patent/US10167276B2/en active Active
-
2018
- 2018-02-06 ZA ZA2018/00782A patent/ZA201800782B/en unknown
- 2018-11-20 US US16/196,038 patent/US10654835B2/en active Active
-
2020
- 2020-04-28 US US16/860,169 patent/US11247983B2/en active Active
-
2021
- 2021-12-28 US US17/563,913 patent/US12319670B2/en active Active